Avoro Capital Advisors LLC — ARROWHEAD PHARMACEUTICALS INC ARWR: Quarterly 13F Position History
Avoro Capital Advisors LLC has reported ARROWHEAD PHARMACEUTICALS INC (ARWR) on 32 13F-HR filings in Pactolio's tracked window, first appearing in Q2 2018. As of Q1 2026, the position is sized at 10,699,999 shares ($670.9M market value, 6.61% of the equity book). Quarter-over-quarter share count change: + 74,999 (+0.7%) .
- 10,699,999Shares Held (Latest Filing)
- $670.9MReported Market Value (Latest Filing)
- 6.61%Portfolio Weight (% of 13F Equity Book)
- +74,999Quarter-over-Quarter Share Change
- -$34.5MQuarter-over-Quarter Value Change
- 11,111,111Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 32 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 10,699,999 | +74,999 | +0.7% | $670.9M | 6.61% | $62.70 |
| Q4 2025 | 10,625,000 | 275,000 | -2.5% | $705.4M | 6.93% | $66.39 |
| Q3 2025 | 10,900,000 | +300,000 | +2.8% | $375.9M | 4.86% | $34.49 |
| Q2 2025 | 10,600,000 | 511,111 | -4.6% | $167.5M | 2.93% | $15.80 |
| Q1 2025 | 11,111,111 | 0 | — | $141.6M | 2.21% | $12.74 |
| Q4 2024 | 11,111,111 | +2,222,223 | +25.0% | $208.9M | 2.95% | $18.80 |
| Q3 2024 | 8,888,888 | 0 | — | $172.2M | 2.51% | $19.37 |
| Q2 2024 | 8,888,888 | +333,333 | +3.9% | $231.0M | 3.08% | $25.99 |
| Q1 2024 | 8,555,555 | +7,425,555 | +657.1% | $244.7M | 2.85% | $28.60 |
| Q4 2023 | 1,130,000 | +565,000 | +100.0% | $34.6M | 0.48% | $30.60 |
| Q3 2023 | 565,000 | +207,597 | +58.1% | $15.2M | 0.24% | $26.87 |
| Q2 2023 | 357,403 | +357,403 | — | $12.7M | 0.17% | $35.66 |
| Q1 2023 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2021 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2021 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2021 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2021 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2020 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2020 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2020 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2020 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2019 | 0 | 0 | — | $0 | 0.00% | — |
| Q3 2019 | 0 | 0 | — | $0 | 0.00% | — |
| Q2 2019 | 0 | 0 | — | $0 | 0.00% | — |
| Q1 2019 | 0 | 0 | — | $0 | 0.00% | — |
| Q4 2018 | 0 | 849,899 | -100.0% | $0 | 0.00% | — |
| Q3 2018 | 849,899 | +399,899 | +88.9% | $16.3M | 0.75% | $19.17 |
| Q2 2018 | 450,000 | — | — | $6.1M | 0.24% | $13.60 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a ARWR position in 13F-HR filings?
Avoro Capital Advisors LLC first reported ARROWHEAD PHARMACEUTICALS INC (ARWR) on its 13F-HR filing for the period ending 2018-06-30 (Q2 2018). The position has appeared on 32 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in ARWR?
Between Q4 2025 and Q1 2026, Avoro Capital Advisors LLC added 74,999 shares of ARWR (+0.7%), bringing the total reported position to 10,699,999 shares at a market value of $670.9M.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in ARWR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.